Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2021-11-05 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司持股5%以上股东、董事集中竞价减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a planned shareholding reduction by a shareholder holding more than 5% of the company's shares. It details the shareholder's identity, shareholding percentage, planned reduction amount, timing, and compliance with relevant securities laws and regulations. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal disclosure of a major shareholding change, specifically a planned reduction in shares held by a significant shareholder. This fits the definition of a Major Shareholding Notification (MRQ). The document length is under 5,000 characters and contains detailed information about the shareholding change, not just a brief mention or a report publication announcement. Therefore, the correct classification is MRQ with high confidence.
2021-11-05 Chinese
圣湘生物科技股份有限公司关于2021年第三次临时股东大会取消部分提案并增加临时提案暨延期召开的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the cancellation and addition of proposals for the 2021 third extraordinary shareholders' meeting, including the postponement of the meeting date. It details the meeting type, original and new dates, voting procedures, and specific agenda items such as profit distribution and stock incentive plans. There is no financial data or detailed report content, but rather an update on the shareholders' meeting arrangements and agenda changes. The document length is short (2194 characters) and it serves as a formal notice about the meeting and its proposals, not the meeting materials or results themselves. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about shareholder meeting changes and agenda updates, not a full report or voting result declaration.
2021-11-03 Chinese
圣湘生物科技股份有限公司2021年三季度利润分配方案补充说明公告
Notice of Dividend Amount Classification · 95% confidence The document is a public announcement from 圣湘生物科技股份有限公司 regarding a supplementary explanation to the 2021 third quarter profit distribution plan. It discusses dividend distribution details, share repurchase effects on dividend base, and mentions the need for shareholder meeting approval. The document is short (1152 characters) and focuses on dividend distribution and related shareholder information rather than presenting full financial statements or detailed quarterly report data. It is not a full interim or quarterly report (IR), nor an earnings release (ER). It is also not a notice of dividend amount (DIV) because it includes detailed explanation about the profit distribution plan and share repurchase impact, which is typical for dividend-related announcements. However, the primary focus is on the profit distribution scheme and its supplementary explanation, which aligns best with a Notice of Dividend Amount (DIV) filing type, as it announces the dividend per share and related details for shareholders.
2021-11-03 Chinese
圣湘生物科技股份有限公司关于以集中竞价交易方式首次回购公司股份暨回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's share repurchase activities, detailing the initial share buyback through centralized bidding, the number of shares repurchased, prices, and compliance with relevant regulations. It does not contain financial statements or detailed financial analysis but focuses on the progress and specifics of the share repurchase program. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2021-11-02 Chinese
圣湘生物股份有限公司监事会关于公司2021年限制性股票激励计划首次授予激励对象名单的审核意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board regarding the review and public disclosure of the initial list of incentive recipients under the company's 2021 restricted stock incentive plan. It includes details about the internal review, public notice, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an official announcement related to a stock incentive plan and the supervisory board's opinion on the eligibility of the recipients. This fits best under Regulatory Filings (RNS) as it is a compliance and disclosure announcement that does not fit other specific categories like capital changes or remuneration reports.
2021-11-02 Chinese
圣湘生物科技股份有限公司关于以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from 圣湘生物科技股份有限公司 regarding a share repurchase plan. It includes specifics about the repurchase purpose, scale, price, funding source, timeline, board approvals, risk factors, and shareholder information. The text repeatedly references the company's plan to buy back shares through centralized bidding, the use of funds, and regulatory compliance. It is not a financial report or earnings release but a formal disclosure about the company's share buyback program. This fits the definition of a Transaction in Own Shares (POS) filing, which covers announcements of share repurchases by the company. The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2021-11-02 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.